Teva And Alvotech Strike US Biosimilars Pact
Deal Covers Five Biosimilar Candidates With $35bn Brand Value
Executive Summary
Teva and Alvotech have announced a major biosimilars alliance covering five products for the US market.
You may also be interested in...
Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone
Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.
Alvotech Reveals Positive Data For Stelara Rival
Alvotech has reported positive results from a study for its AVT04 proposed biosimilar ustekinumab rival to Stelara. The news comes ahead of a key vote on Alvotech’s SPAC merger with Oaktree Capital Management that will take the company public.
Alvotech’s Wessman Sets Out Next Steps On Biosimilars Journey
Alvotech ended 2021 by revealing major plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. In the first part of an exclusive two-part interview, founder and chairman Robert Wessman tells Generics Bulletin how the firm plans to move forward following the transaction.